A new study has advanced our understanding of iron management in chronic kidney disease (CKD) by comparing oral iron to high-dose and low-dose intravenous ferric carboxymaltose (FCM) in patients with predialysis CKD. Intravenous FCM treatment to achieve a higher serum ferritin target improved patient haemoglobin levels and reduced initiation of other anaemia treatments.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fishbane, S., Pollack, S., Feldman, H. I. & Joffe, M. M. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988–2004 Clin. J. Am. Soc. Nephrol. 4, 57–61 (2009).
Stancu, S. et al. Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD. Am. J. Kidney Dis. 55, 639–647 (2010).
Vadasz, D., Ries, V. & Oertel, W. H. Intravenous iron sucrose for restless legs syndrome in pregnant women with low serum ferritin. Sleep Med. 11, 1214–1216 (2013).
Macdougall, I. C. et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anemia. Nephrol. Dial. Transplant. http://dx.doi.org/10.1093/ndt/gfu201.
Pfeffer, M. A. et al. TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 361, 2019–2032 (2009).
Singh, A. K. et al. CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 355, 2085–2098 (2006).
Manns, B. J. & Tonelli, M. The new FDA labeling for ESA—implications for patients and providers. Clin. J. Am. Soc. Nephrol. 7, 348–353 (2012).
Agarwal, R., Vasavada, N., Sachs, N. G. & Chase, S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int. 65, 2279–2289 (2004).
Sengoelge, G. et al. Impairment of transendothelial leukocyte migration by iron complexes. J. Am. Soc. Nephrol. 14, 2639–2644 (2003).
The European Medicines agency EU clinical trials register [online] (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S.F. is a consultant for Keryx Biopharmaceuticals Inc. A.D.H. declares no competing interests.
Rights and permissions
About this article
Cite this article
Fishbane, S., Hazzan, A. FIND-CKD: intravenous iron in predialysis CKD. Nat Rev Nephrol 10, 488–489 (2014). https://doi.org/10.1038/nrneph.2014.139
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2014.139
